These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7346826)

  • 1. Maple syrup urine disease: alpha-ketoisocaproate decarboxylation activity in different types of cultured amniotic fluid cells.
    Wendel U; Gamm G; Claussen U
    Prenat Diagn; 1981 Oct; 1(4):235-40. PubMed ID: 7346826
    [No Abstract]   [Full Text] [Related]  

  • 2. A rapid method for assay of branched-chain keto acid decarboxylation in cultured cells and its application to prenatal diagnosis of maple syrup urine disease.
    Fensom AH; Benson PF; Baker JE
    Clin Chim Acta; 1978 Jul; 87(1):169-74. PubMed ID: 668138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular levels and metabolism of leucine and alpha-ketoisocaproate in normal and maple syrup urine disease fibroblasts.
    Wendel U; Langenbeck U
    Biochem Med; 1984 Jun; 31(3):294-302. PubMed ID: 6477534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maple syrup urine disease: analysis of branched chain ketoacid decarboxylation in cultured fibroblasts.
    Wendel U; Wentrup H; Rüdiger HW
    Pediatr Res; 1975 Sep; 9(9):709-17. PubMed ID: 1202420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antenatal diagnosis of maple-syrup-urine disease.
    Wendel U; Claussen U
    Lancet; 1979 Jan; 1(8108):161-2. PubMed ID: 84186
    [No Abstract]   [Full Text] [Related]  

  • 6. Maple syrup urine disease: coenzyme function and prenatal monitoring.
    Elsas LJ; Priest JH; Wheeler FB; Danner DJ; Pask BA
    Metabolism; 1974 Jun; 23(6):569-79. PubMed ID: 4857216
    [No Abstract]   [Full Text] [Related]  

  • 7. Heterogeneity in maple syrup urine disease: aspects of cofactor requirement and complementation in cultured fibroblasts.
    Singh S; Willers I; Goedde HW
    Clin Genet; 1977 Apr; 11(4):277-84. PubMed ID: 192504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transamination and oxidative decarboxylation rates of branched-chain 2-oxo acids in cultured human skin fibroblasts.
    Schadewaldt P; Radeck W; Hammen HW; Wendel U
    Pediatr Res; 1988 Jan; 23(1):40-4. PubMed ID: 3340442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disturbance of cultured rat neuronal network activity depends on concentration and ratio of leucine and alpha-ketoisocaproate: implication for acute encephalopathy of maple syrup urine disease.
    Görtz P; Köller H; Schwahn B; Wendel U; Siebler M
    Pediatr Res; 2003 Feb; 53(2):320-4. PubMed ID: 12538793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classical maple syrup urine disease: cofactor resistance.
    Elsas LJ; Pask BA; Wheeler FB; Perl DP; Truster S
    Metabolism; 1972 Oct; 21(10):929-44. PubMed ID: 4342010
    [No Abstract]   [Full Text] [Related]  

  • 11. Synaptic plasma membrane Na(+), K (+)-ATPase activity is significantly reduced by the alpha-keto acids accumulating in maple syrup urine disease in rat cerebral cortex.
    Wajner A; Bürger C; Dutra-Filho CS; Wajner M; de Souza Wyse AT; Wannmacher CM
    Metab Brain Dis; 2007 Mar; 22(1):77-88. PubMed ID: 17295076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelin proteins: degradation in rat brain initiated by metabolites causative of maple syrup urine disease.
    Tribble D; Shapira R
    Biochem Biophys Res Commun; 1983 Jul; 114(2):440-6. PubMed ID: 6411085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maple syrup urine disease: branched-chain keto acid decarboxylation in fibroblasts as measured with amino acids and keto acids.
    Dancis J; Hutzler J; Cox RP
    Am J Hum Genet; 1977 May; 29(3):272-9. PubMed ID: 868873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of maple syrup urine disease. Biochemical study].
    Lamedica GM; Fregonese B; Moroni G; Famularo L
    Minerva Pediatr; 1972 Dec; 24(43):2143-9. PubMed ID: 4652219
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of DNA damage by L-carnitine induced by metabolites accumulated in maple syrup urine disease in human peripheral leukocytes in vitro.
    Mescka CP; Wayhs CA; Guerreiro G; Manfredini V; Dutra-Filho CS; Vargas CR
    Gene; 2014 Sep; 548(2):294-8. PubMed ID: 25046137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maple syrup urine disease: two different forms within a single family.
    Frézal J; Amédée-Manesme O; Mitchell G; Heuertz S; Rey F; Rey J; Saudubray JM
    Hum Genet; 1985; 71(1):89-91. PubMed ID: 4029957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biochemical studies in a patient with maple syrup urine disease (author's transl)].
    Vaca G; Rivas F; Sánchez-Corona J; Olivares N; Aguirre-Negrete MG; González-Quiroga G; Medina C; Hernández A; Cantú JM
    Rev Invest Clin; 1981; 33(4):379-82. PubMed ID: 7330511
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of thiamin in maple syrup urine disease.
    Elsas LJ; Danner DJ
    Ann N Y Acad Sci; 1982; 378():404-21. PubMed ID: 7044230
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of maple syrup urine disease in cell culture: use of substrates.
    Schadewaldt P; Beck K; Wendel U
    Clin Chim Acta; 1989 Sep; 184(1):47-56. PubMed ID: 2598467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-trimester diagnosis of maple syrup urine disease on intact chorionic villi.
    Kleijer WJ; Horsman D; Mancini GM; Fois A; Boue J
    N Engl J Med; 1985 Dec; 313(25):1608. PubMed ID: 4069174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.